SEC Form 4 · accession 0001179110-16-026230
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philippe Schaison
Officer — EVP, President Allergan Med
Period of report
Jun 8, 2016
Accepted (ET)
Jun 8, 2016 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1 | holding | — | — | — | 8,620 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $112.20 | holding | — | — | — | — | Oct 31, 2023 | Ordinary Shares | 16,152 | 16,152 | D |
| Stock Option (Right to buy)F3 | $154.87 | holding | — | — | — | — | Feb 21, 2024 | Ordinary Shares | 16,387 | 16,387 | D |
| Stock Option (Right to buy)F4 | $289.75 | holding | — | — | — | — | Feb 20, 2025 | Ordinary Shares | 8,149 | 8,149 | D |
| Stock Option (Right to buy)F5 | $307.51 | holding | — | — | — | — | Mar 17, 2025 | Ordinary Shares | 8,676 | 8,676 | D |
| Performance Based Restricted Stock UnitF6 | — | holding | — | — | — | — | — | Ordinary Shares | 9,344 | 9,344 | D |
Explanation of responses
- F1Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
- F2Vests in four equal annual installments commencing on the first anniversary of the grant date (October 31, 2013).
- F3Vests in four equal annual installments commencing on the first anniversary of the grant date (February 21, 2014).
- F4Vests in four equal annual installments commencing on the first anniversary of the grant date (February 20, 2015).
- F5Vests in five equal annual installments commencing on the first anniversary of the grant date (March 17, 2015).
- F6Represents performance-based restricted share units ("PSUs") which will vest as to one-third of the total grant on each of December 31, 2017, 2018 and 2019, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.